Uric acid: A starring role in the intricate scenario of metabolic syndrome with cardio-renal damage?

Internal and Emergency Medicine

Volumn 7, Issue 1, 2012, Pages 5-8

  Stellato, Davide ^a   Morrone, Luigi Francesco ^a   Di Giorgio, Chiara ^b   Gesualdo, Loreto ^b  

^a G RUMMO HOSPITAL   (Italy)

^b Azienda Ospedaliero Universitaria OORR   (Italy)

Author keywords

Endothelial disfunction; Inflammatory response; Oxidative stress; Uric acid

Indexed keywords

BIOLOGICAL MARKER; URIC ACID;

BLOOD; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; FEMALE; HOSPITALIZATION; HUMAN; HYPERURICEMIA; MALE; METABOLIC SYNDROME X; METABOLISM; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; HYPERURICEMIA; MALE; METABOLIC SYNDROME X; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; URIC ACID;

EID: 84856214207     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-011-0642-3     Document Type: Review

References (36)

1. World Health Organization (1999) Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation. Part 1: diagnosis and classification of diabetes mellitus. Diabet Med 15(7): 539-553. (Available at http://whqlibdoc. who. int/hq/1999/who_ncd_ncs_99. 2. pdf).
2. National Cholesterol Education Program (2002) Third report of the national cholesterol education program (NCEP) on detection and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 106: 3143-3421.
3. Alberti KGM, Zimmet P, Shaw J (2006) Metabolic syndrome: a new world-wide definition. A consensus statement from the International diabetes federation. Diabet Med 23: 469-480.
4. Chen J, Muntner P, Hamm L et al (2004) The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med 140: 167-174.
5. Wahba IM, Mak RH (2007) Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. Clin J Am Soc Nephrol 2: 550-562.
6. Ramirez SP, McClellan W, Port FK et al (2002) Risk factors for proteinuria in a large, multiracial, Southeast Asian population. J Am Soc Nephrol 13: 1907-1917.
7. Tozawa M, Iseki K, Iseki C et al (2002) Influence of smoking and obesity on the development of proteinuria. Kidney Int 62: 956-962.
8. Trayhurn P (2005) Endocrine and signalling role of adipose tissue: new perspectives on fat. Acta Physiol Scand 184: 285-293.
9. Thatcher S, Yiannikouris F, Gupte M et al (2009) The adipose renin-angiotensin system: role in cardiovascular disease. Mol Cell Endocrinol 302: 111-117.
10. Iseki K (2008) Metabolic syndrome and chronic kidney disease: a Japanese perspective on a worldwide problem. J Nephrol 21: 305-312.
11. Gertler MM, Garn SM, Levine SA (1951) Serum uric acid in relation to age and physique in health and in coronary heart disease. Ann Intern Med 34: 1421-1431.
12. Cannon PJ, Stason WB, Demartini FE et al (1966) Hyperuricemia in primary and renal hypertension. N Engl J Med 275: 457-464.
13. Bos MJ, Koudstaal PJ, Hofman A et al (2006) Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam Study. Stroke 37: 1503-1507.
14. Feig DI, Kang DH, Nakagawa T et al (2006) Uric acid and hypertension. Curr Hypertens Rep 8: 111-115.
15. Obermayr RP, Temml C, Knechtelsdorfer M et al (2008) Predictors of new-onset decline in kidney function in a general middle-european population. Nephrol Dial Transplant 23: 1265-1273.
16. Weiner DE, Tighiouart H, Elsayed EF et al (2008) Uric acid and incident kidney disease in the community. J Am Soc Nephrol 19: 1204-1211.
17. K/DOQI (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39(S1): S1-S266.
18. Feig DI, Kang DH, Johnson RJ (2008) Uric acid and cardiovascular risk. N Engl J Med 359: 1811-1821.
19. Feig DI, Johnson RJ (2003) Hyperuricemia in childhood primary hypertension. Hypertension 42: 247-252.
20. Feig DI, Mazzali M, Kang D-H et al (2006) Serum uric acid: a risk factor and a target for treatment? J Am Soc Nephrol 17: S69-S73.
21. Gertzberg N, Neumann P, Rizzo V et al (2004) NAD(P)H oxidase mediates the endothelial barrier dysfunction induced by TNF-alpha. Am J Physiol Lung Cell Mol Physiol 286: L37-L48.
22. Sautin YY, Nakagawa T, Zharikov S et al (2007) Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol 293: C584-C596.
23. Mazzali M, Hughes J, Kim YG et al (2001) Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 38: 1101-1106.
24. Sarafidis PA, Bakris GL (2007) Insulin and endothelin: an interplay contributing to hypertension development? J Clin Endocrinol Metab 92: 379-385.
25. TerMaaten JC, Voorburg A, Heine RJ et al (1997) Renal handling of urate and sodium during acute physiological hyperinsulinaemia in healthy subjects. Clin Sci (Lond) 92: 51-58.
26. Heinig M, Johnson RJ (2006) Role of uric acid in hypertension, renal disease, and metabolic syndrome. Cleve Clin J Med 73: 1059-1064.
27. Hallfrisch J (1990) Metabolic effects of dietary fructose. FASEB J 4: 2652-2660.
28. Viazzi F, Leoncini G, Vercelli M et al (2011) Serum uric acid levels predict new-onset type 2 diabetes in hospitalized patiants with primary hypertension: the MAGIC study. Diabetes Care 34: 126-128.
29. Nakagawa T, Cirillo P, Sato W et al (2009) The conundrum of hyperuricemia, metabolic syndrome, and renal disease. Intern Emerg Med 3: 313-318.
30. Mazzali M, Kanellis J, Han L et al (2002) Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 282: F991-F997.
31. Ames BN, Cathcart R, Schwiers E et al (1981) Uric acid provides an antioxidant defense in humans against oxidant and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 78: 6858-6862.
32. Sautin YY, Johnson RJ (2008) Uric acid: the oxidant-antioxidant paradox. Nucleosides Nucleotides Nucleic Acids 27: 608-619.
33. So A, Thorens B (2010) Uric acid transport and disease. J Clin Invest 120: 1791-1799.
34. Higgins P, Dawson J, Walters M (2009) The potential for xanthine oxidase inhibition in the prevention and treatment of cardiovascular and cerebrovascular disease. Cardiovasc Psychiatry Neurol 2009: 282059.
35. Noman A, Ang DSC, Ogston S et al (2010) Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet 9732: 2161-2167.
36. Goicoechea M, Vinuesa SG, Verdalles U et al (2010) Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 5(8): 1388-1393.